ArticleJournal of thoracic disease2026
The therapeutic effects of dupilumab in asthma-chronic obstructive pulmonary disease overlap and pure asthma: a pilot study.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The efficacy and safety of dupilumab in patients with pure asthma and asthma-COPD overlap (ACO) remain incompletely understood. This single centre pilot study aimed to evaluate the short- and long-term effects of dupilumab on symptom improvement, corticosteroid usage, and safety outcomes in patients with pure asthma and ACO. Methods: We retrospectively analyzed 40 patients aged 12 years or older with asthma treated with dupilumab. The Asthma Control Questionnaire-5 (ACQ-5), mini-Asthma Quality of Life Questionnaire (mini-AQLQ), and modified Medical Research Council Dyspnea Scale (mMRC) were assessed at baseline, day 3, and month 3 after treatment initiation. Corticosteroid usage and safety outcomes were also evaluated. Results: Dupilumab treatment led to significant improvements in asthma symptoms, severity of dyspnea, and quality of life as early as day 3, with sustained effectiveness observed after 3 months. Mean ACQ-5 scores decreased from 3.57±1.39 at baseline to 2.14±1.00 at day 3 and 1.11±0.91 at 3 months (both P<0.001). Mini-AQLQ scores increased from 3.84±1.30 at baseline to 5.20±0.93 at day 3 and 6.14±0.91 at 3 months (P<0.001). Dyspnea severity, assessed by mMRC, also improved at both time points. ACO patients exhibited slightly greater improvements compared with pure asthma patients, although the differences were not statistically significant. The proportion of patients requiring high-dose inhaled corticosteroids (ICS) decreased from 50% at baseline to 22.5% at 3 months. Only one patient discontinued treatment due to elevated blood eosinophil level, and no severe adverse events (AEs) were reported. Conclusions: This study demonstrates that dupilumab is effective in alleviating symptoms in both pure asthma and ACO patients, with rapid and sustained symptom improvement observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.